Table S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Year: 2025
Type: other
Abstract: Safety summary: TEAEs in ≥5% of patients overall and grade ≥3 TEAEs in dose-escalation phase (Q3W schedule)
Authors: Kristoffer Staal Rohrberg, Juanita S. Lopez, Mohammed M. Milhem, Christian U. Blank, Irene Reijers, Fiona Thistlethwaite, Ruth Plummer, Sarina A. Piha-Paul, Pasi A. Jänne, Elaine Shum, Heather M. Shaw, Philip R. Debruyne, Cristopher Lao, Jean-Francois Baurain, Jennifer H. Choe, Eelke Gort, Yujie Zhao, Guy Jerusalem, Patrick Schöffski, Andrew William Chen, Eric A. Cohen, Walter C. Mankowski, Leonid Roshkovan, Sharyn I. Katz, Despina Kontos, Lauren K. Brady, Mohammed Qutaish, Patricia Garrido Castro, Nora Pencheva, Gaurav Bajaj, Yali Fu, Kristian Windfeld, Panagiota Reiter, Maria Jure-Kunkel, Brandon W. Higgs, Katayoun I. Amiri, Tahamtan Ahmadi, Ulf Forssmann, Suresh S. Ramalingam, Ignace Vergote
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416727466
Cites:
Cited by:
Related to: